Please login to the form below

Not currently logged in
Email:
Password:

Jounce

This page shows the latest Jounce news and features for those working in and with pharma, biotech and healthcare.

Celgene cuts back Jounce alliance ahead of BMS merger

Celgene cuts back Jounce alliance ahead of BMS merger

Despite the thinning down of the alliance, the news was greeted enthusiastically by Jounce investors, with its shares rising more than 30% on Wednesday. ... Jounce must now deliver positive results from its phase 2 EMERGE clinical trial of vopratelimab

Latest news

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    Licensee. Licensor. Headline. Upfront. Equity. Near-term R&D funding. Celgene. Jounce. $2, 561m. ... Jounce Therapeutics/ Celgene. Portfolio and platform of biomarker driven immuno-oncology therapeutics and CDx.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...

Infographics